Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504383 | 1.00 | TSHR (0.50) | TSHRMAPTALOX15HSD17B10NPC1 | |
| SCHEMBL19996347 | 1.00 | TSHR (0.50) | TSHRMAPTALOX15HSD17B10NPC1 | |
| Hydrochloric Acid SCHEMBL19742945 | 0.98 | TSHR (0.48) | TSHRMAPTALOX15HSD17B10NPC1 | |
| SCHEMBL24119 | 0.98 | TSHR (0.52) | TSHRMAPTALOX15HSD17B10NPC1 | |
| SCHEMBL28370547 | 0.98 | TSHR (0.52) | TSHRMAPTALOX15HSD17B10NPC1 | |
| SCHEMBL29373532 | 0.98 | TSHR (0.52) | TSHRMAPTALOX15HSD17B10NPC1 | |
| SCHEMBL7247288 | 0.96 | TSHR (0.50) | TSHRMAPTALOX15HSD17B10NPC1 | |
| Hydrochloric Acid SCHEMBL28292055 | 0.96 | TSHR (0.50) | TSHRMAPTALOX15HSD17B10NPC1 | |
| SCHEMBL28370551 | 0.94 | TSHR (0.54) | TSHRMAPTALOX15HSD17B10NPC1 | |
| SCHEMBL28345077 | 0.94 | TSHR (0.48) | TSHRMAPTALOX15HSD17B10NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0566069-A1 | Tachykinin receptor antagonists, isoquinolones and their production | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-10-20 | — | — | EP | claimed |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-12-05 | — | — | US | disclosed |
| EP-4445902-A2 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2024-10-16 | — | — | EP | disclosed |
| EP-4081305-B1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | CARNA BIOSCIENCES INC (JP) | 2024-09-18 | — | — | EP | disclosed |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | GILEAD SCIENCES, INC. (US) | 2023-12-19 | — | — | US | disclosed |
| EP-4122537-A1 | BRIDGED TRICYCLIC CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-4081305-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | Carna Biosciences, Inc. (JP) | 2022-11-02 | — | — | EP | disclosed |
| WO-1991005549-A1 | BENZOHETEROCYCLIC COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | WO | disclosed |
| US-4929622-A | ANALGESICS | HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) | 1990-05-29 | — | — | US | disclosed |
| EP-0308913-A2 | 2,6-Methanopyrrolo-3-benzazocines, a process and intermediates for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1989-03-29 | — | — | EP | disclosed |
| US-4205171-A | ANALGESICS | STERLING DRUG INC. (US) | 1980-05-27 | — | — | US | disclosed |
| US-4165371-A | ANALGESICS | RESEARCH CORPORATION (US) | 1979-08-21 | — | — | US | disclosed |
| US-RE29943-E | ANALGESICS | STERLING DRUG INC. (US) | 1979-03-20 | — | — | US | disclosed |
| US-4127577-A | Aminomethanobenzazocine process | STERLING DRUG INC. (US) | 1978-11-28 | — | — | US | disclosed |
| US-4032529-A | ANALGESICS | STERLING DRUG INC. (US) | 1977-06-28 | — | — | US | disclosed |
| US-3968114-A | ANALGESIC | STERLING DRUG INC. (US) | 1976-07-06 | — | — | US | disclosed |
| US-3957793-A | ANALGESICS | STERLING DRUG INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400568-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | TSHR 3739/4885MAPT 4206/4885ALOX15 2014/4885 |
| US-12054490-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | TSHR 3739/4885MAPT 4206/4885ALOX15 2014/4885 |
| US-11845723-B2 | Diacylglycerol kinase modulating compounds | DGKG, DGKB, DGKK | TSHR 3739/4885MAPT 4206/4885ALOX15 2014/4885 |
| US-20240182476-A1 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | TSHR 3739/4885MAPT 4206/4885ALOX15 2014/4885 |
| US-20250361236-A9 | DIACYLGLYCEROL KINASE MODULATING COMPOUNDS | DGKG, DGKB, DGKK | TSHR 3739/4885MAPT 4206/4885ALOX15 2014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.